NEW YORK, March 24, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action on behalf of persons or entities who purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025.So What: If you purchased Zynex secur ...

SAN DIEGO, March 21, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYXI) securities between March 13, 2023 to March 11, 2025. Zynex is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management and physical rehabilitation.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The All ...

NEW YORK, March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Zynex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On March 11, 2025, Zynex reported i ...

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ:ZYXI). The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On March 11, 2025, after market hours, Zynex released its fourth quarter and full year 2024 financial results, revealing a revenue ...

Core Insights - Zynex, Inc. reported lower than expected revenue for the fourth quarter and full year ended December 31, 2024, primarily due to slower payments from certain payers and a temporary suspension of payments by Tricare as they review prior claims [1] Company Summary - Zynex, Inc. is currently under investigation by Holzer & Holzer, LLC to determine if the company complied with federal securities laws following the disappointing financial results announcement [1] - The announcement of the revenue shortfall led to a decline in Zynex's stock price [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

The mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companies, offering the Seeking Alpha investor compelling points of view on these often overlooked investment opportunities; and periodically identifying potential opportunities in large- and mega-cap companies, expanding the scope to provide encompassing coverage ...

Financial Data and Key Metrics Changes - Net revenue for Q4 2024 was $46 million, a decrease from $47.3 million in Q4 2023 [33] - Device revenue decreased to $14.8 million from $16.3 million year-over-year, while supplies revenue increased slightly to $31.2 million from $31 million [33] - Gross profit remained stable at $36 million, representing 78% of revenue, consistent with the previous year [34] - Net loss for Q4 2024 was $615,000, compared to a net income of $1.2 million in Q4 2023 [35] - Adjusted EBITDA fell to $584,000 from $9.9 million in the same quarter last year [35] Business Line Data and Key Metrics Changes - Revenue increased by 4% in 2024, with order growth at 16% [24] - Average revenue per sales representative increased by 22% to $490,000 in 2024, despite a reduction in the total number of sales representatives from approximately 475 to 330 [24] Market Data and Key Metrics Changes - The patient monitoring business is expected to enter a multi-billion dollar market with the anticipated FDA clearance of the NiCO pulse oximeter [32] - The company is optimistic about capturing identified sales opportunities within its designated sales territories, estimated at $800 million [13] Company Strategy and Development Direction - The company is diversifying its revenue streams by adding new products, including private label products in bracing and compression [7] - Focus on expanding the sales force to new prescribers, including national workers' compensation chains and the VA [7] - The company aims to maintain a long-term growth vision despite short-term disruptions, emphasizing the importance of product diversification [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term prospects of the company, despite challenges related to Tricare's temporary payment suspension [12][37] - The company is restructuring to optimize its cost structure and has implemented measures to ensure long-term growth and profitability [11][15] - Revenue guidance for 2025 remains uncertain due to the lack of visibility surrounding Tricare payments, with an anticipated Q1 revenue of approximately $30 million [39] Other Important Information - Tricare's temporary suspension of payments could significantly impact revenue, as it represents 20% to 25% of total revenue [19] - The company is undergoing a staff reduction of 15%, primarily affecting corporate office employees, which is expected to result in annual savings of approximately $35 million [23] Q&A Session Summary Question: What was accomplished in the fourth quarter regarding staff reductions? - The company achieved about $30 million in annual savings, with less than half realized in 2024, and expects further reductions in sales and G&A expenses [46][47] Question: What is the commercial path to market for the NiCO pulse oximeter? - The strategy includes direct sales, partnerships with distributors, and an indirect sales force to penetrate the market upon FDA clearance [52][54] Question: What was the nature of the 2022 audit by Tricare? - The audit was a routine post-payment audit with standard adjustments suggested, and no major issues were identified [58] Question: Why is there a lack of visibility into sales for 2025? - The uncertainty is primarily due to Tricare's significant role in revenue, and the company is cautious about providing guidance until more clarity is obtained [61] Question: What is the plan for the upcoming meeting with Tricare? - The company will present data from the 2022 audit and highlight compliance with previous adjustments during the appeal meeting [64] Question: Could other payers follow Tricare's lead in reviewing claims? - Management does not foresee a connection between Tricare's actions and other payers, emphasizing that each operates independently [70]

NASDAQ: ZYXI Investor Presentation July 2024 Forward Looking Statement This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated ev ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Financial Performance - Net revenue increased by $8.0 million or 4% to $192.4 million for the year ended December 31, 2024, compared to $184.3 million in 2023[218] - The company recorded a net income of $3.0 million for 2024, down from $9.7 million in 2023, marking a decrease of 69%[218] - Operating cash flows were reported at $12.7 million, a decrease of 28% or $5.0 million from the previous year[219] - Net cash provided by operating activities decreased to $12.7 million in 2024 from $17.8 million in 2023, primarily due to lower profitability and a decrease in accounts payable[242] Revenue Breakdown - Device orders grew by 16%, contributing to a 1% increase in device revenue to $59.6 million for the year ended December 31, 2024[230] - Supplies revenue increased by $7.2 million or 6% to $132.7 million for the year ended December 31, 2024, driven by a larger customer base[231] - Costs of revenue for devices and supplies increased by $1.1 million or 3% to $39.4 million, but as a percentage of revenue, it decreased to 20% from 21%[232][233] Expenses and Cost Management - General and administrative expenses increased by 24% to $60.4 million for the year ended December 31, 2024, compared to $48.5 million in 2023, representing 31% of revenue, up from 26% in 2023[235] - Sales and marketing expenses decreased slightly to $86.6 million, with a reduction in percentage of revenue from 47% to 45%[234] - The company is restructuring its staff, reducing overall headcount by approximately 10%, which is expected to save about $35 million annually[215] - Other expenses for the year ended December 31, 2024, were $2.4 million, primarily due to interest expense on Senior Convertible Notes, while other income in 2023 was $1.8 million[236] Cash Flow and Financing Activities - Net cash used in financing activities for the year ended December 31, 2024, was $17.1 million, mainly due to $15.6 million in treasury stock purchases[244] - The company repurchased approximately $15.6 million worth of common stock due to strong cash flow results[214] - The company issued $52.5 million in 5.00% Convertible Senior Notes in May 2023, with an additional $7.5 million from an over-allotment option[240] Tax and Working Capital - Income tax expense decreased to $0.6 million for the year ended December 31, 2024, with an effective tax rate of 17%, down from $2.8 million and 23% in 2023[237] - Working capital as of December 31, 2024, was $58.3 million, down from $69.3 million in 2023, with cash and cash equivalents at $39.6 million and accounts receivable at $18.0 million[238] Business Risks and Strategic Planning - TriCare, representing approximately 20-25% of annual revenue, temporarily suspended payments, prompting the company to seek reinstatement[214] - The company acknowledges risks and uncertainties in forward-looking statements, which could materially affect actual results[10] - Management's discussion includes expectations regarding future operations, margins, and profitability, highlighting strategic planning[10] - The company does not assume an obligation to update forward-looking statements, indicating a cautious approach to future projections[11] Asset Management and Valuation - The company allocates the purchase price of acquired companies to tangible and intangible assets based on estimated fair values, with excess recorded as goodwill[265] - Goodwill impairment assessments are conducted annually, with potential triggers including significant decreases in market price and adverse changes in business climate[266] - Contingent consideration liabilities related to business acquisitions are classified within Level 3, with fair value estimated using a Monte Carlo simulation[267] - The company emphasizes the uncertainty in management's estimates of fair value, which could lead to impairment of intangible assets if assumptions are not met[265] - Future cash flows from long-lived assets must exceed carrying values to avoid write-downs, indicating a focus on asset performance[266] - Significant adverse changes in legal or regulatory factors may trigger impairment reviews, reflecting the company's responsiveness to external conditions[266] - The company utilizes independent third-party valuation specialists for fair value assessments, ensuring accuracy in financial reporting[265]